DNA Methylation-Derived Immune Cell Proportions and Cancer Risk, Including Lung Cancer, in Black Participants.

TitleDNA Methylation-Derived Immune Cell Proportions and Cancer Risk, Including Lung Cancer, in Black Participants.
Publication TypeJournal Article
Year of Publication2024
AuthorsSemancik, CS, Zhao, N, Koestler, DC, Boerwinkle, E, Bressler, J, Buchsbaum, RJ, Kelsey, KT, Platz, EA, Michaud, DS
JournalmedRxiv
Date Published2024 May 09
Abstract

Prior cohort studies assessing cancer risk based on immune cell subtype profiles have predominantly focused on White populations. This limitation obscures vital insights into how cancer risk varies across race. Immune cell subtype proportions were estimated using deconvolution based on leukocyte DNA methylation markers from blood samples collected at baseline on participants without cancer in the Atherosclerosis Risk in Communities (ARIC) Study. Over a mean of 17.5 years of follow-up, 668 incident cancers were diagnosed in 2,467 Black participants. Cox proportional hazards regression was used to examine immune cell subtype proportions and overall cancer incidence and site-specific incidence (lung, breast, and prostate cancers). Higher T regulatory cell proportions were associated with statistically significantly higher lung cancer risk (hazard ratio = 1.22, 95% confidence interval = 1.06-1.41 per percent increase). Increased memory B cell proportions were associated with significantly higher risk of prostate cancer (1.17, 1.04-1.33) and all cancers (1.13, 1.05-1.22). Increased CD8+ naïve cell proportions were associated with significantly lower risk of all cancers in participants ≥55 years (0.91, 0.83-0.98). Other immune cell subtypes did not display statistically significant associations with cancer risk. These results in Black participants align closely with prior findings in largely White populations. Findings from this study could help identify those at high cancer risk and outline risk stratifying to target patients for cancer screening, prevention, and other interventions. Further studies should assess these relationships in other cancer types, better elucidate the interplay of B cells in cancer risk, and identify biomarkers for personalized risk stratification.

DOI10.1101/2024.05.09.24307118
Alternate JournalmedRxiv
PubMed ID38766207
PubMed Central IDPMC11100922
Grant ListRC2 HL102419 / HL / NHLBI NIH HHS / United States
75N92022D00002 / HL / NHLBI NIH HHS / United States
R01 NS087541 / NS / NINDS NIH HHS / United States
75N92022D00004 / HL / NHLBI NIH HHS / United States
75N92022D00003 / HL / NHLBI NIH HHS / United States
75N92022D00005 / HL / NHLBI NIH HHS / United States
U01 CA164975 / CA / NCI NIH HHS / United States
75N92022D00001 / HL / NHLBI NIH HHS / United States